PBK/TOPK promotes chemoresistance to oxaliplatin in hepatocellular carcinoma cells by regulating PTEN

Oxaliplatin (OXA) resistance limits the efficiency of treatment for hepatocellular carcinoma (HCC). Studies have shown that PDZ-binding kinase (PBK) plays important roles in tumors. However, role PBK HCC is still a problem. In this study, we explored whether involved chemoresistance to OXA HCC. Expressions six cell lines and one human hepatocytes line were determined by real-time quantitative PCR western blot analysis. SNU-182 HepG2 cells chosen induce resistance. was silenced or overexpressed OXA-resistant sensitive lines. Then, proliferation, migration, invasion measured cholecystokinin-8 assay Transwell assay, respectively. The Cancer Genome Atlas dataset showed highly expressed signifies poor prognosis patient with Results expression significantly higher than THLE2 cells, it further increased cells. Silencing promoted sensitivity drug-resistant OXA. Overexpression relieved apoptosis induced migration OXA-sensitive Thus, study revealed high correlated which may provide promising therapeutic target treating